Abstract
Introduction: The novel coronavirus disease 2019 (COVID-19), is caused by the severe acute respiratory syndrome cronavirus 2 (SARS-CoV2). The management of cancer patients is very challenging during the COVID-19 pandemic. Cancer itself as well as anticancer treatment leads to compromised immunity of patients with increased risk of infection. This is turn leads to increased hospital visits. It forms a vicious cycle that increases the risk of COVID-19 susceptibility to cancer patients. Patients on anticancer treatment alongwith COVID-19 infection have higher risk of morbidity and mortality. Aim: To compare the epidemiological characteristics and management decisions in gallbladder cancer patients during COVID-19 pandemic. Methods: This retrospective study was conducted at All India Institute of Medical Sciences (AIIMS), Patna. Patients were divided into two group pre-COVID (patients attending radiotherapy department from December 2019 to February 2020) and established-COVID group patients (patients attending radiotherapy department from March 2020 to May 2020) with histopathological confirmed diagnosis of gallbladder cancer. Results: Histopathological confirmed cases of gallbladder cancer (n=85) were analyzed, 56 patients from pre-COVID timeline and 29 patients from established-COVID timeline were selected. During the pre-COVID timeline, 55.4% of the patients directly visited the radiotherapy department while, 24.1% patients directly attended the radiotherapy department during the established-COVID time. This reduction of number of patients at radiotherapy department was statistically significant (p = 0.006). There was statistically significant reduction (p = 0.014) in number of patients attending from rural areas during established-COVID time. Chemotherapy regimen used during pre-COVID and establishedCOVID timeline was significantly (p < 0.001) different. Conclusion: Cancer patient management during COVID-19 pandemic is an important issue. Chemotherapy increases the risk of COVID-19 infection by reducing the immunity. Single agent oral capecitabine is a good option for patients of gallbladder cancer in the adjuvant or palliative settings with less toxicity and requiring less hospital visits compared to intravenous chemotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
